January2017

News Hour: Rapper Soulja Boy was charged on Monday with possessing an assault weapon and receiving stolen property following a December raid at his Hollywood home by police, Los Angeles prosecutors said. The rapper, whose real...

News Hour: Talk show host Stephen Colbert will host the 2017 Emmys ceremony celebrating the highest honors in television, organizers said on Monday. It will be the first time Colbert hosts the annual ceremony which takes...

News Hour: Former champion Stan Wawrinka engaged in a war of words with Jo-Wilfried Tsonga before winning the only argument that mattered on Tuesday, storming into the Australian Open semi-finals with a 7-6(2) 6-4 6-3 win...

News Hour: Liverpool’s formidable home record was meant to provide the platform for a tilt at three trophies this season — but Saturday’s surprise 3-2 Premier League defeat by Swansea spoiled that idea. If Jurgen Klopp’s...

News Hour: Ahmed Elmohamady knows what it takes to win the Africa Cup of Nations and the Hull City man is quietly confident that Egypt can go all the way again on their long-awaited return to...

News Hour: GARMENTECH Bangladesh-2017 showcased the latest apparel technology in its 16th edition. Renowned technology leaders from all over the world attended the 4-day event held from 18 to 21 January 2017 at the International Convention City...

News Hour: MSD, known as Merck & Co., Inc., Kenilworth, N.J., U.S.A., inside the United States and Canada, announced today its $10 million commitment to the Global Financing Facility (GFF) in support of Every Woman Every...

News Hour: Giving men with suspected prostate cancer an MRI scan could improve diagnosis and save those who do not have aggressive cancers from having an unnecessary biopsy, according to a study published in The Lancet....

News Hour: Grameenphone in association with Smartphone brand OPPO, has announced bundle offer with two new devices, OPPO F1s and A33F. The devices and offer were announced at an event held at GP House in the...

News Hour: Sanofi announced that the European Commission has granted marketing authorization in Europe for SuliquaTM, the once-daily titratable fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of...